View Future GrowthSolesence 過去の業績過去 基準チェック /16Solesenceは、平均年間5%の収益成長を遂げていますが、 Chemicals業界の収益は、年間 減少しています。収益は、平均年間3.8% 21.2%収益成長率で 成長しています。 Solesenceの自己資本利益率は10.2%であり、純利益率は2.9%です。主要情報5.00%収益成長率-5.44%EPS成長率Chemicals 業界の成長12.93%収益成長率21.18%株主資本利益率10.15%ネット・マージン2.88%次回の業績アップデート12 May 2026最近の業績更新お知らせ • Mar 20Solesence, Inc. to Report Q4, 2025 Results on Mar 31, 2026Solesence, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 31, 2026お知らせ • Oct 30Solesence, Inc. to Report Q3, 2025 Results on Nov 11, 2025Solesence, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 11, 2025お知らせ • Jul 24Solesence, Inc. to Report Q2, 2025 Results on Jul 31, 2025Solesence, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025お知らせ • Apr 29Solesence, Inc. to Report Q1, 2025 Results on May 05, 2025Solesence, Inc. announced that they will report Q1, 2025 results After-Market on May 05, 2025お知らせ • Oct 25Nanophase Technologies Corporation to Report Q3, 2024 Results on Oct 30, 2024Nanophase Technologies Corporation announced that they will report Q3, 2024 results at 4:00 PM, US Eastern Standard Time on Oct 30, 2024お知らせ • Jul 30Nanophase Technologies Corporation to Report Q2, 2024 Results on Aug 06, 2024Nanophase Technologies Corporation announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 06, 2024すべての更新を表示Recent updatesお知らせ • Apr 29+ 1 more updateSolésence, Inc. Announces Appointment of Marc James as Independent Director and Member of Committees, Effective April 27, 2026Solésence, Inc. announced the appointment of Marc James to its Board of Directors as an independent director, effective April 27, 2026. James will also serve as a member of the Company’s Audit Committee, Compensation Committee, and Nominating Committee. The appointment reflects Solésence’s continued focus on maintaining its strong corporate governance and enhancing board expertise as the Company advances its Transform & Transcend strategic initiative and long-term growth objectives. James is an accomplished executive with deep experience in global financial markets, having served in senior managing director roles advising corporate clients on capital markets activities, interest rate risk management, and financing strategies. His background spans finance, strategy, and governance, making him well-positioned to contribute to Solésence’s next phase of growth.お知らせ • Mar 20Solesence, Inc. to Report Q4, 2025 Results on Mar 31, 2026Solesence, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 31, 2026お知らせ • Oct 30Solesence, Inc. to Report Q3, 2025 Results on Nov 11, 2025Solesence, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 11, 2025お知らせ • Sep 03+ 2 more updatesSolésence, Inc. Announces Chief Executive Officer ChangesSolésence, Inc. announced strategic changes to its executive leadership. Kevin Cureton, a driving force behind the company’s expansion and innovation, will assume the role of Chief Executive Officer. Jess Jankowski, who has been at the helm of the company as Chief Executive Officer since 2009, will serve as Board Advisor until his retirement from the company and its Board of Directors on November 21, 2025. Effective immediately, these leadership changes are part of a wider strategic transformation for the company. In the first half of 2025, Solésence rebranded from Nanophase Technologies, a move that reflected the success of the Solésence Beauty Science platform and resolidified the company’s mission to deliver joy through innovation, inclusivity and the science of beautiful skin.お知らせ • Jul 31Solesence, Inc., Annual General Meeting, Aug 28, 2025Solesence, Inc., Annual General Meeting, Aug 28, 2025. Location: companys corporate headquarters, 1319 marquette drive, romeoville, illinois, United Statesお知らせ • Jul 24Solesence, Inc. to Report Q2, 2025 Results on Jul 31, 2025Solesence, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025Seeking Alpha • Jun 22Solesence: Flying Close To The Sun (Rating Downgrade)Summary Solesence Inc., formerly Nanophase Technologies, specializes in zinc oxide nanoparticles for skincare and cosmetics. Solesence has a $360 million market cap, and though previously under the radar, is being added to the Russell 3000 index and up-listed to the NASDAQ. The shares have climbed rapidly over the last 6 months in spite of operational challenges resulting in reduced gross profits, and stretching the valuation. Read the full article on Seeking Alphaお知らせ • Apr 29Solesence, Inc. to Report Q1, 2025 Results on May 05, 2025Solesence, Inc. announced that they will report Q1, 2025 results After-Market on May 05, 2025お知らせ • Apr 10Nanophase Technologies Corporation COM Deleted from OTC EquityNanophase Technologies Corporation COM has been deleted from OTC Equity effective April 08, 2025, due to Market Center Change Listed on NASDAQ.お知らせ • Dec 26Nanophase Technologies Corporation Approves Directorate AppointmentsNanophase Technologies Corporation approved Election of two director nominees. Jess A. Jankowski and Mark E. Miller.お知らせ • Oct 25Nanophase Technologies Corporation to Report Q3, 2024 Results on Oct 30, 2024Nanophase Technologies Corporation announced that they will report Q3, 2024 results at 4:00 PM, US Eastern Standard Time on Oct 30, 2024お知らせ • Aug 07Nanophase Technologies Corporation Provides Revenue Guidance for the Second Half of 2024 and Earnings Guidance for the Rest of 2024Nanophase Technologies Corporation provided revenue guidance for the second half of 2024 and earnings guidance for the rest of 2024. With the company's second half revenue expected to exceed first half performance by more than 20%, the company remain poised to continue the strong revenue growth that has been the hallmark of the past five years for the Company. The company now demonstrating margin performance above the company's industry averages enabled by the company's focus on both operational improvements and financial management to lower costs and contain expenses. The company sharing the company's positive outlook for the rest of 2024.お知らせ • Jul 30Nanophase Technologies Corporation to Report Q2, 2024 Results on Aug 06, 2024Nanophase Technologies Corporation announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 06, 2024お知らせ • Apr 21Nanophase Technologies Corporation to Report Q1, 2024 Results on Apr 23, 2024Nanophase Technologies Corporation announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on Apr 23, 2024お知らせ • Apr 11Nanophase Technologies Corporation Announces Successful Litigation Settlement with BASFNanophase Technologies Corporation announced that it has agreed to a successful and amicable resolution of all ongoing litigation with BASF. The parties have executed a Settlement Agreement, an amendment to their existing supply contract, and a joint stipulation to dismiss the case with prejudice to be filed in the Superior Court of New Jersey within the next five business days.お知らせ • Mar 06Nanophase Technologies Corporation to Report Fiscal Year 2023 Results on Mar 20, 2024Nanophase Technologies Corporation announced that they will report fiscal year 2023 results on Mar 20, 2024お知らせ • Nov 23Nanophase Technologies Corporation has filed a Follow-on Equity Offering in the amount of $2 million.Nanophase Technologies Corporation has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: $0.4 Transaction Features: Rights Offeringお知らせ • Nov 08Nanophase Technologies Corporation to Report Q3, 2023 Results on Nov 13, 2023Nanophase Technologies Corporation announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 13, 2023お知らせ • Nov 07Nanophase Technologies Corporation, Annual General Meeting, Nov 15, 2023Nanophase Technologies Corporation, Annual General Meeting, Nov 15, 2023, at 08:30 Central Standard Time. Location: headquarters, 1319 Marquette Drive, Romeoville, Illinois, Illinois United States Agenda: To ratify the appointment by the Company’s Audit and Finance Committee of RSM US LLP as the independent auditors of the Company’s financial statements for the year ending December 31, 2023; to transact such other business as may properly come before the meeting or any adjournments ; and to consider other matters if any.お知らせ • Jul 29Nanophase Technologies Corporation to Report Q2, 2023 Results on Aug 02, 2023Nanophase Technologies Corporation announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 02, 2023お知らせ • Jul 23Mark E. Miller Joins Nanophase Technologies Corporation's Board of Directors, Effective as of July 19, 2023Nanophase Technologies Corporation announced the appointment of Mark E. Miller to its Board of Directors. Miller, a veteran of many of the industries and markets served by Nanophase, and its wholly owned subsidiary Solésence LLC, brings 36 years of leadership and commercial experience in specialty materials and chemicals in the Personal Care, Pharma, CASE, and Metals markets. Miller was most recently the President & COO of Nagase Specialty Materials NA LLC (Itasca, IL) before departing in April 2023. Miller’s appointment as an independent director is effective as of July 19, 2023.お知らせ • May 10Nanophase Technologies Corporation to Report Q1, 2023 Results on May 11, 2023Nanophase Technologies Corporation announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 11, 2023お知らせ • Dec 03Nanophase Technologies Corporation, Annual General Meeting, Dec 14, 2022Nanophase Technologies Corporation, Annual General Meeting, Dec 14, 2022, at 08:30 Central Standard Time. Location: 1319 Marquette Drive Romeoville United States Agenda: To elect two Class I directors to the Company’s Board of Directors; to consider the approval of the advisory vote on the compensation paid to our named executive officers; to ratify the appointment by the Company’s Audit and Finance Committee of RSM US LLP as the independent auditors of the Company’s financial statements for the year ending December 31, 2022; and to transact such other business as may properly come before the meeting or any adjournments thereof.お知らせ • Nov 02Nanophase Technologies Corporation to Report Q3, 2022 Results on Nov 08, 2022Nanophase Technologies Corporation announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 08, 2022お知らせ • Sep 08BASF Files a Complaint against NanophaseNanophase Technologies Corporation on September 7, 2022 filed an 8-K referencing that BASF, one of its customers, filed a complaint against Nanophase in the Superior Court of New Jersey. Among other things, the complaint alleges that Nanophase breached the exclusivity provisions of a supply agreement through the sale of zinc oxide based products through its Solésence subsidiary. In response to BASF’s action, Nanophase has in turn filed a Complaint for Declaratory Judgment in the Circuit Court of Cook County regarding the exclusivity terms within the agreement. While management is disappointed that it has come to this point after two decades of supply to BASF and over a half-decade of operating the Solésence business, the Company is fully confident in its position and will take the necessary steps to defend it.お知らせ • Aug 17Nanophase Technologies Corporation announced delayed 10-Q filingOn 08/16/2022, Nanophase Technologies Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 13Nanophase Technologies Corporation to Report Q2, 2022 Results on Aug 17, 2022Nanophase Technologies Corporation announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 17, 2022お知らせ • May 05Nanophase Technologies Corporation to Report Q1, 2022 Results on May 11, 2022Nanophase Technologies Corporation announced that they will report Q1, 2022 results After-Market on May 11, 2022お知らせ • Mar 31Nanophase Technologies Corporation to Report Q4, 2021 Results on Mar 31, 2022Nanophase Technologies Corporation announced that they will report Q4, 2021 results After-Market on Mar 31, 2022お知らせ • Mar 03Solésence Beauty Science Expands to Australian Market as Nanophase Technologies Receives TGA GMP Site ClearanceSolésence Beauty Science announced that it has been issued TGA GMP site clearance for the full finished product manufacture of creams, lotions, sprays, sticks and all topical sunscreen forms. The site clearance has been granted to Nanophase Technologies, of which Solésence is a wholly owned subsidiary. An innovation-driven beauty science company, Solésence finished goods offer brands patented formulas that leverage an ever-expanding suite of environmental protection technologies within their own Active Stress Defense™ platform. These technologies, which target aggressors such as UV, pollution and HEV (blue) light, are only available through the finished goods that they develop and manufacture. TGA GMP site clearance signals the possibility of expansion into Australian markets.お知らせ • Nov 14Nanophase Technologies Corporation, Annual General Meeting, Dec 09, 2020Nanophase Technologies Corporation, Annual General Meeting, Dec 09, 2020, at 08:30 Central Standard Time. Location: 1319 Marquette Drive Romeoville Illinois United States Agenda: To elect one Class II director to the Company’s Board of Directors; to ratify the appointment by the Company’s Audit and Finance Committee of RSM US LLP as the independent auditors of the Company’s financial statements for the year ending December 31, 2020; and to transact such other business as may properly come before the meeting or any adjournments thereof.お知らせ • Nov 06Nanophase Technologies Corporation Appoints Laura M. Beres to the Audit and Finance Committee, Compensation Committee, and Nominating and Corporate Governance CommitteeNanophase Technologies Corporation Laura M. Beres has been appointed to the Audit and Finance Committee, Compensation Committee, and Nominating and Corporate Governance Committee.お知らせ • Oct 30Nanophase Technologies Corporation Appoints Laura M. Beres to its Board of DirectorsNanophase Technologies Corporation announced the appointment of Laura M. Beres to its Board of Directors. Beres’ appointment as an independent director is effective as of October 28, 2020. Beres is director of corporate strategy at Ulta Beauty. Beres leads Conscious Beauty at Ulta Beauty, a holistic program that offers enhanced transparency and choice around clean ingredients and sustainability.収支内訳Solesence の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:SLSN 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 2562210430 Sep 2562110430 Jun 256459431 Mar 255738431 Dec 245247430 Sep 244837430 Jun 2439-27431 Mar 2438-27431 Dec 2337-48430 Sep 2338-48430 Jun 2339-49431 Mar 2339-48331 Dec 2237-38330 Sep 2236-16330 Jun 223515331 Mar 223114231 Dec 212924230 Sep 212734230 Jun 212324231 Mar 212023231 Dec 201713230 Sep 201503230 Jun 2014-13231 Mar 2013-33231 Dec 1913-34230 Sep 1913-34230 Jun 1914-24231 Mar 1915-23231 Dec 1814-23230 Sep 1814-13230 Jun 1812-23231 Mar 1812-23231 Dec 1712-13230 Sep 1712-13230 Jun 1712-13231 Mar 1712-13231 Dec 1611-13230 Sep 1611-13130 Jun 1611-13131 Mar 1610-13131 Dec 1510-13130 Sep 1510-23130 Jun 1510-231質の高い収益: SLSN 非現金収入 のレベルが高いです。利益率の向上: SLSNの現在の純利益率 (2.9%)は、昨年(8.1%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SLSN過去 5 年間で収益を上げており、収益は年間5%増加しています。成長の加速: SLSNは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: SLSNは過去 1 年間で収益成長率がマイナス ( -57.7% ) となったため、 Chemicals業界平均 ( 0.7% ) と比較することが困難です。株主資本利益率高いROE: SLSNの 自己資本利益率 ( 10.2% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 14:47終値2026/05/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Solesence, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 20Solesence, Inc. to Report Q4, 2025 Results on Mar 31, 2026Solesence, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 31, 2026
お知らせ • Oct 30Solesence, Inc. to Report Q3, 2025 Results on Nov 11, 2025Solesence, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 11, 2025
お知らせ • Jul 24Solesence, Inc. to Report Q2, 2025 Results on Jul 31, 2025Solesence, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025
お知らせ • Apr 29Solesence, Inc. to Report Q1, 2025 Results on May 05, 2025Solesence, Inc. announced that they will report Q1, 2025 results After-Market on May 05, 2025
お知らせ • Oct 25Nanophase Technologies Corporation to Report Q3, 2024 Results on Oct 30, 2024Nanophase Technologies Corporation announced that they will report Q3, 2024 results at 4:00 PM, US Eastern Standard Time on Oct 30, 2024
お知らせ • Jul 30Nanophase Technologies Corporation to Report Q2, 2024 Results on Aug 06, 2024Nanophase Technologies Corporation announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 06, 2024
お知らせ • Apr 29+ 1 more updateSolésence, Inc. Announces Appointment of Marc James as Independent Director and Member of Committees, Effective April 27, 2026Solésence, Inc. announced the appointment of Marc James to its Board of Directors as an independent director, effective April 27, 2026. James will also serve as a member of the Company’s Audit Committee, Compensation Committee, and Nominating Committee. The appointment reflects Solésence’s continued focus on maintaining its strong corporate governance and enhancing board expertise as the Company advances its Transform & Transcend strategic initiative and long-term growth objectives. James is an accomplished executive with deep experience in global financial markets, having served in senior managing director roles advising corporate clients on capital markets activities, interest rate risk management, and financing strategies. His background spans finance, strategy, and governance, making him well-positioned to contribute to Solésence’s next phase of growth.
お知らせ • Mar 20Solesence, Inc. to Report Q4, 2025 Results on Mar 31, 2026Solesence, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 31, 2026
お知らせ • Oct 30Solesence, Inc. to Report Q3, 2025 Results on Nov 11, 2025Solesence, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 11, 2025
お知らせ • Sep 03+ 2 more updatesSolésence, Inc. Announces Chief Executive Officer ChangesSolésence, Inc. announced strategic changes to its executive leadership. Kevin Cureton, a driving force behind the company’s expansion and innovation, will assume the role of Chief Executive Officer. Jess Jankowski, who has been at the helm of the company as Chief Executive Officer since 2009, will serve as Board Advisor until his retirement from the company and its Board of Directors on November 21, 2025. Effective immediately, these leadership changes are part of a wider strategic transformation for the company. In the first half of 2025, Solésence rebranded from Nanophase Technologies, a move that reflected the success of the Solésence Beauty Science platform and resolidified the company’s mission to deliver joy through innovation, inclusivity and the science of beautiful skin.
お知らせ • Jul 31Solesence, Inc., Annual General Meeting, Aug 28, 2025Solesence, Inc., Annual General Meeting, Aug 28, 2025. Location: companys corporate headquarters, 1319 marquette drive, romeoville, illinois, United States
お知らせ • Jul 24Solesence, Inc. to Report Q2, 2025 Results on Jul 31, 2025Solesence, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025
Seeking Alpha • Jun 22Solesence: Flying Close To The Sun (Rating Downgrade)Summary Solesence Inc., formerly Nanophase Technologies, specializes in zinc oxide nanoparticles for skincare and cosmetics. Solesence has a $360 million market cap, and though previously under the radar, is being added to the Russell 3000 index and up-listed to the NASDAQ. The shares have climbed rapidly over the last 6 months in spite of operational challenges resulting in reduced gross profits, and stretching the valuation. Read the full article on Seeking Alpha
お知らせ • Apr 29Solesence, Inc. to Report Q1, 2025 Results on May 05, 2025Solesence, Inc. announced that they will report Q1, 2025 results After-Market on May 05, 2025
お知らせ • Apr 10Nanophase Technologies Corporation COM Deleted from OTC EquityNanophase Technologies Corporation COM has been deleted from OTC Equity effective April 08, 2025, due to Market Center Change Listed on NASDAQ.
お知らせ • Dec 26Nanophase Technologies Corporation Approves Directorate AppointmentsNanophase Technologies Corporation approved Election of two director nominees. Jess A. Jankowski and Mark E. Miller.
お知らせ • Oct 25Nanophase Technologies Corporation to Report Q3, 2024 Results on Oct 30, 2024Nanophase Technologies Corporation announced that they will report Q3, 2024 results at 4:00 PM, US Eastern Standard Time on Oct 30, 2024
お知らせ • Aug 07Nanophase Technologies Corporation Provides Revenue Guidance for the Second Half of 2024 and Earnings Guidance for the Rest of 2024Nanophase Technologies Corporation provided revenue guidance for the second half of 2024 and earnings guidance for the rest of 2024. With the company's second half revenue expected to exceed first half performance by more than 20%, the company remain poised to continue the strong revenue growth that has been the hallmark of the past five years for the Company. The company now demonstrating margin performance above the company's industry averages enabled by the company's focus on both operational improvements and financial management to lower costs and contain expenses. The company sharing the company's positive outlook for the rest of 2024.
お知らせ • Jul 30Nanophase Technologies Corporation to Report Q2, 2024 Results on Aug 06, 2024Nanophase Technologies Corporation announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 06, 2024
お知らせ • Apr 21Nanophase Technologies Corporation to Report Q1, 2024 Results on Apr 23, 2024Nanophase Technologies Corporation announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on Apr 23, 2024
お知らせ • Apr 11Nanophase Technologies Corporation Announces Successful Litigation Settlement with BASFNanophase Technologies Corporation announced that it has agreed to a successful and amicable resolution of all ongoing litigation with BASF. The parties have executed a Settlement Agreement, an amendment to their existing supply contract, and a joint stipulation to dismiss the case with prejudice to be filed in the Superior Court of New Jersey within the next five business days.
お知らせ • Mar 06Nanophase Technologies Corporation to Report Fiscal Year 2023 Results on Mar 20, 2024Nanophase Technologies Corporation announced that they will report fiscal year 2023 results on Mar 20, 2024
お知らせ • Nov 23Nanophase Technologies Corporation has filed a Follow-on Equity Offering in the amount of $2 million.Nanophase Technologies Corporation has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: $0.4 Transaction Features: Rights Offering
お知らせ • Nov 08Nanophase Technologies Corporation to Report Q3, 2023 Results on Nov 13, 2023Nanophase Technologies Corporation announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 13, 2023
お知らせ • Nov 07Nanophase Technologies Corporation, Annual General Meeting, Nov 15, 2023Nanophase Technologies Corporation, Annual General Meeting, Nov 15, 2023, at 08:30 Central Standard Time. Location: headquarters, 1319 Marquette Drive, Romeoville, Illinois, Illinois United States Agenda: To ratify the appointment by the Company’s Audit and Finance Committee of RSM US LLP as the independent auditors of the Company’s financial statements for the year ending December 31, 2023; to transact such other business as may properly come before the meeting or any adjournments ; and to consider other matters if any.
お知らせ • Jul 29Nanophase Technologies Corporation to Report Q2, 2023 Results on Aug 02, 2023Nanophase Technologies Corporation announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 02, 2023
お知らせ • Jul 23Mark E. Miller Joins Nanophase Technologies Corporation's Board of Directors, Effective as of July 19, 2023Nanophase Technologies Corporation announced the appointment of Mark E. Miller to its Board of Directors. Miller, a veteran of many of the industries and markets served by Nanophase, and its wholly owned subsidiary Solésence LLC, brings 36 years of leadership and commercial experience in specialty materials and chemicals in the Personal Care, Pharma, CASE, and Metals markets. Miller was most recently the President & COO of Nagase Specialty Materials NA LLC (Itasca, IL) before departing in April 2023. Miller’s appointment as an independent director is effective as of July 19, 2023.
お知らせ • May 10Nanophase Technologies Corporation to Report Q1, 2023 Results on May 11, 2023Nanophase Technologies Corporation announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 11, 2023
お知らせ • Dec 03Nanophase Technologies Corporation, Annual General Meeting, Dec 14, 2022Nanophase Technologies Corporation, Annual General Meeting, Dec 14, 2022, at 08:30 Central Standard Time. Location: 1319 Marquette Drive Romeoville United States Agenda: To elect two Class I directors to the Company’s Board of Directors; to consider the approval of the advisory vote on the compensation paid to our named executive officers; to ratify the appointment by the Company’s Audit and Finance Committee of RSM US LLP as the independent auditors of the Company’s financial statements for the year ending December 31, 2022; and to transact such other business as may properly come before the meeting or any adjournments thereof.
お知らせ • Nov 02Nanophase Technologies Corporation to Report Q3, 2022 Results on Nov 08, 2022Nanophase Technologies Corporation announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 08, 2022
お知らせ • Sep 08BASF Files a Complaint against NanophaseNanophase Technologies Corporation on September 7, 2022 filed an 8-K referencing that BASF, one of its customers, filed a complaint against Nanophase in the Superior Court of New Jersey. Among other things, the complaint alleges that Nanophase breached the exclusivity provisions of a supply agreement through the sale of zinc oxide based products through its Solésence subsidiary. In response to BASF’s action, Nanophase has in turn filed a Complaint for Declaratory Judgment in the Circuit Court of Cook County regarding the exclusivity terms within the agreement. While management is disappointed that it has come to this point after two decades of supply to BASF and over a half-decade of operating the Solésence business, the Company is fully confident in its position and will take the necessary steps to defend it.
お知らせ • Aug 17Nanophase Technologies Corporation announced delayed 10-Q filingOn 08/16/2022, Nanophase Technologies Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 13Nanophase Technologies Corporation to Report Q2, 2022 Results on Aug 17, 2022Nanophase Technologies Corporation announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 17, 2022
お知らせ • May 05Nanophase Technologies Corporation to Report Q1, 2022 Results on May 11, 2022Nanophase Technologies Corporation announced that they will report Q1, 2022 results After-Market on May 11, 2022
お知らせ • Mar 31Nanophase Technologies Corporation to Report Q4, 2021 Results on Mar 31, 2022Nanophase Technologies Corporation announced that they will report Q4, 2021 results After-Market on Mar 31, 2022
お知らせ • Mar 03Solésence Beauty Science Expands to Australian Market as Nanophase Technologies Receives TGA GMP Site ClearanceSolésence Beauty Science announced that it has been issued TGA GMP site clearance for the full finished product manufacture of creams, lotions, sprays, sticks and all topical sunscreen forms. The site clearance has been granted to Nanophase Technologies, of which Solésence is a wholly owned subsidiary. An innovation-driven beauty science company, Solésence finished goods offer brands patented formulas that leverage an ever-expanding suite of environmental protection technologies within their own Active Stress Defense™ platform. These technologies, which target aggressors such as UV, pollution and HEV (blue) light, are only available through the finished goods that they develop and manufacture. TGA GMP site clearance signals the possibility of expansion into Australian markets.
お知らせ • Nov 14Nanophase Technologies Corporation, Annual General Meeting, Dec 09, 2020Nanophase Technologies Corporation, Annual General Meeting, Dec 09, 2020, at 08:30 Central Standard Time. Location: 1319 Marquette Drive Romeoville Illinois United States Agenda: To elect one Class II director to the Company’s Board of Directors; to ratify the appointment by the Company’s Audit and Finance Committee of RSM US LLP as the independent auditors of the Company’s financial statements for the year ending December 31, 2020; and to transact such other business as may properly come before the meeting or any adjournments thereof.
お知らせ • Nov 06Nanophase Technologies Corporation Appoints Laura M. Beres to the Audit and Finance Committee, Compensation Committee, and Nominating and Corporate Governance CommitteeNanophase Technologies Corporation Laura M. Beres has been appointed to the Audit and Finance Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
お知らせ • Oct 30Nanophase Technologies Corporation Appoints Laura M. Beres to its Board of DirectorsNanophase Technologies Corporation announced the appointment of Laura M. Beres to its Board of Directors. Beres’ appointment as an independent director is effective as of October 28, 2020. Beres is director of corporate strategy at Ulta Beauty. Beres leads Conscious Beauty at Ulta Beauty, a holistic program that offers enhanced transparency and choice around clean ingredients and sustainability.